UK markets open in 1 hour 53 minutes
  • NIKKEI 225

    30,148.76
    +477.06 (+1.61%)
     
  • HANG SENG

    30,352.54
    +634.30 (+2.13%)
     
  • CRUDE OIL

    63.45
    +0.23 (+0.36%)
     
  • GOLD FUTURES

    1,799.50
    +1.60 (+0.09%)
     
  • DOW

    31,961.86
    +424.51 (+1.35%)
     
  • BTC-GBP

    35,593.66
    -502.27 (-1.39%)
     
  • CMC Crypto 200

    1,006.89
    +12.23 (+1.23%)
     
  • ^IXIC

    13,597.97
    0.00 (0.00%)
     
  • ^FTAS

    3,795.06
    +23.72 (+0.63%)
     

Notice of Results

·2-min read

Arix Bioscience PLC (ARIX)
11-Feb-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

Notice of Results

LONDON, 11 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its annual results for the year ended 31 December 2020, on Tuesday 9th March 2021.

Arix will host a virtual analyst presentation on the same day, at 12:00pm GMT, followed by a Q&A session, accessible via conference call or webcast. The webcast of the presentation will be available on the Company's investor relations website at https://arixbioscience.com/investor-relations/events-presentations.

For details of the conference call please contact optimum.arix@optimumcomms.com.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com

Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

NOR

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

93411

EQS News ID:

1167627


 

End of Announcement

EQS News Service

show this
show this